Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 367Ovarian Neoplasms 99Lung Neoplasms 98Neoplasms 84Small Cell Lung Carcinoma 71Breast Neoplasms 59Neoplasm Metastasis 49Triple Negative Breast Neoplasms 46Parkinson Disease 4, Autosomal Dominant Lewy Body 41Fallopian Tube Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Endometrial Neoplasms 30Carcinoma 30Uterine Cervical Neoplasms 28Colorectal Neoplasms 24Carcinoma, Ovarian Epithelial 23Head and Neck Neoplasms 19Carcinoma, Transitional Cell 18Urinary Bladder Neoplasms 17Advanced Solid Tumors 17Recurrence 15Melanoma 14Stomach Neoplasms 13Peritoneal Neoplasms 13Pancreatic Neoplasms 12Adenocarcinoma 11Lung Diseases 9Glioblastoma 9Carcinoma, Squamous Cell 9Thoracic Neoplasms 8

Interventions

Gemcitabine 4Cisplatin 4Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1avelumab 1atezolizumab 1Tiragolumab 1Sunitinib 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Urothelial Cancer × Carboplatin × Clear all
NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

AstraZeneca

Phase 3 Active not recruiting
1,126 enrolled 52 charts
Genitourinary

Urothelial Cancer

NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡